Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to new SVP, Market Access and Health Policy, Kelley Allison, under its 2019 Inducement Stock Incentive Plan in line with Nasdaq Rule 5635(c)(4).
Awards include options for 85,000 shares at $8.99 and 28,000 RSUs with multi‑year vesting.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – OCUL
+1.45%
16 alerts
+1.45%News Effect
+6.8%Peak Tracked
-9.5%Trough Tracked
+$33MValuation Impact
$2.32BMarket Cap
1.4xRel. Volume
On the day this news was published, OCUL gained 1.45%, reflecting a mild positive market reaction.
Argus tracked a peak move of +6.8% during that session.
Argus tracked a trough of -9.5% from its starting point during tracking.
Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
This price movement added approximately $33M to the company's valuation, bringing the market cap to $2.32B at that time.
This announcement details inducement equity awards of 85,000 options and 28,000 RSUs for a new SVP, ...
Analysis
This announcement details inducement equity awards of 85,000 options and 28,000 RSUs for a new SVP, continuing OCUL’s use of stock-based compensation. An effective shelf and recent insider selling highlight dilution and governance as key risks to monitor.
Key Figures
Stock options granted:85,000 sharesRSUs granted:28,000 sharesOption exercise price:$8.99 per share+4 more
7 metrics
Stock options granted85,000 sharesInducement non-statutory stock option to new SVP on June 15, 2026
RSUs granted28,000 sharesInducement restricted stock units to new SVP on June 15, 2026
Option exercise price$8.99 per shareEqual to OCUL June 15, 2026 Nasdaq closing price
Option term10 yearsNon-statutory stock option duration for inducement grant
Option vesting period4 years25% after one year, remainder monthly over next three years
Initial vesting tranche25%Of original option shares vest on first anniversary of grant
RSU vesting period3 yearsRSUs vest in three equal annual installments
Equity inducement awards to new SVP, Head of HR with multi-year vesting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
OCUL tends to move sharply on pipeline/FDA updates, while routine governance and compensation items often see weak or negative price follow-through.
Key Terms
nasdaq listing rule 5635(c)(4), non-statutory stock option, restricted stock unit, inducement stock incentive plan
4 terms
nasdaq listing rule 5635(c)(4)regulatory
"inducement grants under Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-statutory stock optionfinancial
"consist of a non-statutory stock option award to purchase up to 85,000 shares"
A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.
restricted stock unitfinancial
"restricted stock unit awards representing the right to receive an aggregate of 28,000 shares"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
inducement stock incentive planfinancial
"under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq"
An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company’s new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards granted to Ms. Allison were effective as of June 15, 2026 and consist of a non-statutory stock option award to purchase up to 85,000 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 28,000 shares of Ocular’s common stock. Ms. Allison’s stock option award has an exercise price of $8.99 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option award has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit awards vest over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com
FAQ
What inducement equity grants did Ocular Therapeutix (NASDAQ: OCUL) announce on June 22, 2026?
Ocular Therapeutix announced inducement equity grants for its new SVP, Kelley Allison, including stock options and restricted stock units. According to Ocular, the awards were made under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
How many Ocular Therapeutix (OCUL) shares are covered by Kelley Allison’s inducement stock option grant?
Kelley Allison received a non-statutory stock option to purchase up to 85,000 Ocular Therapeutix common shares. According to Ocular, the option has a ten-year term, an exercise price of $8.99 per share, and vests over four years, subject to continued service.
What are the vesting terms for Kelley Allison’s stock options at Ocular Therapeutix (OCUL)?
The stock options vest 25% on the one-year anniversary of the June 15, 2026 grant date. According to Ocular, the remaining 75% vests in equal monthly installments over the following three years, contingent on Ms. Allison’s continued employment with the company.
What restricted stock units did Ocular Therapeutix (OCUL) grant to Kelley Allison as an inducement award?
Ocular Therapeutix granted restricted stock units representing 28,000 common shares to Kelley Allison. According to Ocular, these RSUs vest in three equal annual installments on the first, second, and third anniversaries of the grant date, subject to her continued service with the company.
At what exercise price were Ocular Therapeutix (OCUL) inducement stock options granted to Kelley Allison?
The inducement stock options were granted at an exercise price of $8.99 per share. According to Ocular, this price equals the closing price of Ocular Therapeutix common stock on the Nasdaq Global Market on June 15, 2026, the effective grant date.
Under which plan and rule were Ocular Therapeutix (OCUL) inducement awards to Kelley Allison granted?
The inducement awards were granted under Ocular Therapeutix’s 2019 Inducement Stock Incentive Plan. According to Ocular, these awards were approved as a material inducement to employment and structured in compliance with Nasdaq Listing Rule 5635(c)(4) requirements for equity grants.
